
Marico Q4 Results: Profit rises 8% to ₹343 crore, volume growth beats estimates; dividend declared
Marico, a leading player in India's consumer products sector with a focus on hair and wellness, announced its March quarter results post-market hours today, May 02, reporting a mixed performance. The company reported volume growth of 7% in its India business, which was higher than analyst estimates of 5–6%.
It also reported constant currency growth of 16% in the international business. Consolidated and India revenue growth, as well as underlying volume growth in the India business, stood at a 14-quarter high, as per the company's earnings filing.
The company stated that its India business continued to deliver sequential improvement in volume growth during the quarter. It witnessed the transient impact of hyperinflation and resultant steep price increases in core portfolios but maintained robust momentum in its new businesses.
Offtakes remained strong, with 95% of the business gaining or sustaining market share and 80% gaining or sustaining penetration, both on a MAT basis. India's revenues stood at ₹ 2,068 crore, up 23% YoY, aided by price hikes in core portfolios in response to elevated input costs.
The international business delivered another stellar quarter and closed ahead of the company's internal targets. However, gross margin contracted by 300 basis points YoY, primarily due to the rise in copra and vegetable oil prices, which was partly offset by pricing interventions in key portfolios.
A&P spends were up 35% YoY in Q4 (and up 18% in FY25), in line with the company's strategic intent to continually strengthen its franchises and accelerate diversification. Consequently, EBITDA rose 4% to ₹ 458 crore, with EBITDA margin at 16.8%, down 260 basis points. Net profit increased 8% YoY to ₹ 343 crore.
For FY25, revenue from operations stood at ₹ 10,831 crore, up 12% YoY, with underlying volume growth of 5% in the India business and constant currency growth of 14% in the international business. Profit for FY25 stood at ₹ 1,629 crore, marking a 10% YoY increase.
At its meeting held on May 02, 2025, the Board of Directors recommended a final dividend of ₹ 7 per equity share of ₹ 1 each on its paid-up equity share capital of approximately ₹ 129.5 crore.
Marico expects gradually improving growth trends in the core categories of its India business, supported by moderating retail and food inflation and the forecast of a healthy monsoon season.
The company believes this will be further aided by its ongoing initiatives to support select General Trade (GT) channel partners and the transformative expansion of its direct reach footprint under Project SETU.
Marico also said it continues to draw confidence from healthy offtakes, penetration, and market share gains in its key portfolios. It further stated that it remains focused on driving differential growth in its urban-centric and premium portfolios through organized retail and e-commerce channels.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
17 hours ago
- Time of India
Nestle India's permanent employee count down 3.8% in FY25
The number of permanent employees in Nestle India fell 3.8 per cent in FY25, though the maker of Maggi and KitKat increased its capex and is investing in new capabilities and capacities. The total number of on-roll employees of Nestle India was 8,419 in FY25, as compared to 8,736 a year ago. The increase in the median remuneration of employees in last fiscal year was 4.9 per cent. "The median percentage increase made in the salaries of employees other than the managerial personnel was 5.2 per cent while the increase in the remuneration of managerial personnel was 3.5 per cent," said Nestle India . Nestle India, which reported over Rs 20,000 crore sales in FY25, increased capex level from 1.8 per cent of sales in 2015 to 10 per cent of sales in FY25, said its outgoing Chairman Suresh Narayanan , while addressing the shareholders. The maker of Maggi, Nescafe and KitKat has already announced a succession plan, appointing Manish Tiwary as a Director and Managing Director for a five-year term effective August 1, 2025. Tiwary has been appointed as Managing Director (Designate) from February 1, 2025 and as Key Managerial Personnel from April 24, 2025. For the two months of service, Tiwary was paid a remuneration of nearly Rs 3 crore. "During financial year 2024-25, Manish Tiwary was paid a remuneration of Rs 29.94 million. Additionally, as per the terms agreed by the Board of Directors with Manish Tiwary, he was given a lump sum payout of Rs 151.96 million, with applicable tax deducted at source, at the time of joining the company to compensate for his long-term incentives loss...," said Nestle India. In FY25, total remuneration of CMD Suresh Narayanan was at Rs 23.47 crore.


Mint
a day ago
- Mint
IREDA share price dips 2% as it launches QIP to raise ₹5000 crore: Here are key details
Stock Market Today: IREDA share price declined up to 2% in the morning trade on Friday The Renewable Energy firm launched a QIP to raise ₹ 5000 crore: Here are key details As per details provided by Indian Renewable Energy Development Agency Ltd of IREDA and with reference to the meeting of Board of Directors held on January 23, 2025, followed by approval of the shareholders of the Company by way of a special resolution passed on February 24, 2025, the Board of Directors of IREDA, at its meeting held on June 5, 2025, announced details pertaining to the QIP or qualified institutional placement. The QIP dates - The Board of IREDA authorized the opening of the proposed Issue today, i.e., on June 5, 2025, to eligible qualified institutional buyers; Floor Price of the QIP- The approved the floor price for the Issue stands at ₹ 173.83 per Equity Share. The floor price was around 1.5% lower than the previous days closing levels of ₹ 176.50 for IREDA share price on the BSE. IREDA QIP discount: The company may offer a discount of up to 5% on the floor price as per the approval received from the shareholder approval. Issue Price: IREDA said that the Issue price will be determined by the Company in consultation with the book running lead managers appointed for the Issue. In the same context, the company has announced that the trading window shall remain closed for the purpose of the QIP Issue till further intimation- IREDA share price Movement - In December 2023, IREDA share price had been listed on the stocks exchange and the share price has given Multibagger returns to investors, rising by about 7 times compared to the IPO offer price of ₹ 32. While IREDA share price had risen to highs of ₹ 310 e in July 2024, it had corrected to ₹ 137 in MArch 2025. However the IREDA share price has rebounded well thereafter


Hans India
2 days ago
- Hans India
Indian medtech startup rings bell in NY, celebrates Nasdaq debut
Hyderabad: In a defining leap for Indian medical technology on the global stage, SS Innovations International, the creators of the indigenous SSI Mantra surgical robotic system — rang the opening bell on Wednesday at the Nasdaq Market Site in New York City. The company's shares are listed under the ticker symbol 'SSII'. The ceremony was led by Dr Sudhir Srivastava, Founder, Chairman, and CEO of SS Innovations International, joined by members of the company's management team, Board of Directors, key advisors, and special guests. This milestone marks a proud moment for India, underscoring the nation's growing leadership in advanced medical technologies and heralding a new era of innovation and international recognition for Indian-origin healthcare solutions. SS Innovations International has made remarkable progress with its clinically validated and patented SSI Mantra Surgical Robotic System, which has been installed in 80 hospitals across 75 locations in India. The company has also expanded its presence internationally to countries including Nepal, Ecuador, Guatemala, the Philippines, Indonesia, Sri Lanka, Colombia and Ukraine. With over 4,000 successful robotic surgeries completed across more than 100 surgical procedures, the SSI Mantra is transforming access to advanced robotic surgery by offering a cost-effective solution to a broader patient population.